Phase I dose-escalation trial of Sym004, an anti-EGFR antibody mixture, in Japanese patients with advanced solidtumors

Sym004 is a 1:1 mixture of two antibodies targeting non-overlapping epitopes of the epidermal growth factor receptor that antagonizes ligand binding and induces receptor downregulation. In preclinical models, it has superior antitumor activity to cetuximab and panitumumab. Japanese adults aged 20years with an Eastern Cooperative Oncology Group status of 0/1 and life expectancy 3months were eligible. Patients in Part A (dose escalation) had refractory or recurrent late-stage solid tumors and received Sym004 6mg/kg/wk (n=3), 9mg/kg loading/6mg/kg/wk (n=6), 12mg/kg/wk (n=6), or 18mg/kg biweekly (n=6). Patients in expansion Part B (n=30) had esophageal squamous cell carcinoma and received Sym004 at the dose recommended from Part A. Fifty-one patients received Sym004. No dose-limiting toxicities were observed in Part A. A dose of 12mg/kg/wk was selected for Part B. All patients in Part B experienced treatment-related adverse events, most commonly dermatitis acneiform (76.7%). Eighteen grade 3 treatment-related adverse events and five serious adverse events occurred (cardiac arrest, lung infection, interstitial lung disease, toxic skin eruption, blood creatinine increase). Two patients had treatment-related adverse events resulting in death (cardiac arrest and blood creatinine increase). Five patients in Part B had a best overall response of partial response, 12 stable diseases and 12 disease progression (1 not evaluable). The objective response rate was 16.7% (95% CI: 5.6%-34.7%). Sym004 therapy was well tolerated with no dose-limiting toxicities at any dose studied. Evidence of antitumor activity was seen in patients with esophageal squamous cell carcinoma. ClinicalTrials.gov Identifier: NCT01955473.